Rapamycin Plus Bevacizumab in Advanced Cancers

Status Completed

Clinical Trial Summary

The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00667485
Study type	Interventional
Source	University of Chicago
Contact
Status	Completed
Phase	Phase 1
Start date	April 2008
Completion date	May 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Not yet recruiting	`NCT04931420` - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels	Phase 2
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Withdrawn	`NCT00005030` - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver	Phase 1
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting	`NCT04085029` - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Not yet recruiting	`NCT05981170` - Rurality Adapted Physical Activity Sport Health
Not yet recruiting	`NCT03058809` - Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood	Phase 1/Phase 2
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Completed	`NCT01302808` - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT00918645` - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis	N/A
Completed	`NCT00795678` - Chemotherapeutic Agents in Brain/Breast	N/A
Withdrawn	`NCT00769990` - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases	Phase 1/Phase 2
Completed	`NCT00557102` - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung	Phase 2
Recruiting	`NCT00398437` - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer	N/A